Basmisanil

Drug Profile

Basmisanil

Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; RG-1662; RO5186582

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
  • Mechanism of Action GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Down syndrome; Neurological disorders; Schizophrenia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Down syndrome in Japan (PO, Tablet)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Down syndrome(In volunteers) in United Kingdom (PO, Granules)
  • 21 Apr 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top